Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 27, 2017. The report primarily discloses information pursuant to section 430(2B) of the Companies Act 2006 regarding the departure of former executives and the updated composition of the Board of Directors effective April 1, 2017.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and executive remuneration disclosures.
Material Changes
- Executive Departures: Sir Andrew Witty (former CEO) and Dr. Moncef Slaoui (former President, R&D) stood down from the Board on March 31, 2017, via mutual agreement.
- Leadership Transition: Emma Walmsley succeeded Sir Andrew Witty as Chief Executive Officer on April 1, 2017.
- Board Composition: The Board was reconstituted effective April 1, 2017, with Sir Philip Hampton serving as Non-Executive Chairman and Simon Dingemans as Chief Financial Officer.
- Director Departure: Ms. Stacey Cartwright stepped down as a Non-Executive Director on December 31, 2016.
Guidance, Outlook, and Management Commentary
Remuneration Treatment for Departing Executives:
- Termination Payments: No termination payments will be made to Sir Andrew Witty or Dr. Moncef Slaoui.
- 2017 Bonus: Both executives will receive on-target bonus payments pro-rated for the portion of the financial year worked.
- Equity Awards: No new 2017 Performance Share Plan (PSP) awards or Deferred Annual Bonus Plan (DABP) matching awards will be granted. Existing awards from 2016, 2015, and 2014 will vest at normal dates subject to performance conditions.
- Shareholding Requirement: Both executives must maintain their shareholding requirements for at least 12 months after leaving the Company.
- Dr. Slaoui's Advisory Role: Dr. Slaoui served as an advisor to GSK and the Board from April 1, 2017, until June 30, 2017, under existing contractual remuneration arrangements, subject to final confirmation by the Remuneration Committee.
- Ms. Cartwright: Received only fees for service as a Director; no payment for loss of office was made.
Future Disclosure: Full details of all payments to Sir Andrew Witty and Dr. Moncef Slaoui following their departure will be included in the Company's 2017 Annual Report.
Investor Verification Checklist
- Verify the final vesting status of 2014-2016 equity awards for Sir Andrew Witty and Dr. Moncef Slaoui in the 2017 Annual Report.
- Confirm the total cost of pro-rated 2017 bonuses and advisory fees for Dr. Slaoui once the 2017 Annual Report is published.
- Review the 2017 Annual Report for the complete breakdown of payments made to departing executives as required by the Companies Act 2006.
- Monitor the strategic direction under the new leadership of CEO Emma Walmsley and CFO Simon Dingemans.